Advertisement
The study, published in the November issue of Clinical Therapeutics: TheInternational Peer-Reviewed Journal of Drug Therapy, shows that people who usethe 21 mg NicoDerm CQ nicotine patch every day for the first 21 days ofquitting were three-times as likely of being smoke-free at the six week pointin the course of treatment compared to those who do not wear their patch everyday.(2) Further, when used as directed, the NicoDerm CQ patch cansignificantly increase a smoker's chance of quitting (versus placebo) andremaining smoke-free long-term (6 months or longer).(3)
Advertisement
"Quitting smoking can be one of the toughest New Year's resolutions tokeep. The NicoDerm CQ nicotine patch is a hassle free approach to quittingsmoking as smokers only need to apply it once-daily," said Saul Shiffman,Ph.D., lead researcher and professor in the departments of psychology andpharmaceutical science at the University of Pittsburgh. "While a smoker mayslip and have a cigarette during the quitting process, by no means should theyabandon quitting altogether. Smokers should keep wearing the NicoDerm CQpatch every day and it will keep working for you, even if you slip."
To help smokers get started on their pre-New Year's resolutions, NicoDermCQ is offering a new bonus pack, which offers a free week of nicotine patchesduring a smoker's first step of therapy. For more information, smokerslooking to quit can visit http://www.nicodermcq.com/21days.
Over-the-counter therapeutic nicotine products like the NicoDerm CQ patch,Nicorette gum and Commit lozenge are first-line treatments for smokingcessation and are thoroughly researched, well-understood and highly accessiblestop smoking therapies.(4) GlaxoSmithKline Consumer Healthcare's therapeuticnicotine products are available without a doctor's prescription, in flexibledosing options at over 35,000 retail outlets across the country.(5) So asmoker who wants to quit doesn't have to wait to see a doctor to get help.
About NicoDerm CQ patch
NicoDerm CQ is the number one doctor-recommended patch to quit smoking.In fact, no treatment -- prescription or OTC -- is proven more effective thanNicoderm CQ in helping smokers quit long term.(5) NicoDerm CQ comes in threedifferent strengths -- all specially formulated to control the release ofnicotine for 24 hours. As cravings begin to diminish, this three-step processprovides smokers with a lower dosage in each step, which allows a smoker towean off nicotine gradually and safely. As with any treatment, failure toadhere to dosing instructions on the product label can limit effectiveness.When used as directed, NicoDerm CQ allows a smoker's body to gradually adjustto having less nicotine until eventually he doesn't need any at all. It alsohelps calm the cravings that make quitting smoking so hard by preventingcravings before they occur and providing more effective relief of cravingsthan willpower alone. Research has shown that using NicoDerm CQ to quitsmoking significantly improves your chances of quitting successfully versusquitting cold turkey.(3)
About GlaxoSmithKline Consumer Healthcare
GlaxoSmithKline Consumer Healthcare is one of the world's largestover-the-counter consumer healthcare products companies. Its more than 30well-known brands include the leading smoking cessation products, Nicorette(R)and NicoDerm(R)CQ(R), and Commit(R), as well as many medicine cabinet staples-- alli(R), Aquafresh(R), Sensodyne(R), and TUMS(R) -- which are trademarksowned by and/or licensed to GlaxoSmithKline Group of Companies.
About GlaxoSmithKline
GlaxoSmithKline -- one of the world's leading research-basedpharmaceutical and healthcare companies -- is committed to improving thequality of human life by enabling people to do more, feel better and livelonger. For company information visit: http://www.gsk.com.(1) Survey of 808 adult smokers interested in quitting conducted by GlaxoSmithKline Consumer Healthcare in October 2006. (2) Shiffman S, Sweeney CT, Ferguson S, et al. Adherence with Nicotine Patch Dosing and Treatment Efficacy: Secondary Analysis of a 10-Week Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Over-the-Counter Patch in Adult Smokers. (3) Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews. 1996, Issue 3. (4) Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. May 2008. (5) GSK Data on file. Contacts: Mark Polisky, GolinHarris 312-729-4417 [email protected] Jennifer May, GlaxoSmithKline Consumer Healthcare 412-200-3729 [email protected]
SOURCE GlaxoSmithKline Consumer Healthcare
